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en bloc: 86.3%See editorial on page 1101.BACKGROUND AND AIMS: Endoscopic submucosal dissection
(ESD) enables the curative resection of early malignant
lesions and is associated with reduced recurrence risk. Due
to the lack of comprehensive ESD data in the West, the
German ESD registry was set up to evaluate relevant out-
comes of ESD. METHODS: The German ESD registry is a
prospective uncontrolled multicenter study. During a
35-month period, 20 centers included 1000 ESDs of neoplastic
lesions. The results were evaluated in terms of en bloc, R0,
curative resection rates, and recurrence rate after a 3-month
and 12-month follow-up. Additionally, participating centers
were grouped into low-volume (20 ESDs/y), middle-volume
(20–50/y), and high-volume centers (>50/y). A multivariateanalysis investigating risk factors for noncurative resection
was performed. RESULTS: Overall, en bloc, R0, and curative
resection rates of 92.4% (95% confidence interval [CI],
0.90–0.94), 78.8% (95% CI, 0.76–0.81), and 72.3% (95% CI,
0.69-0.75) were achieved, respectively. The overall complica-
tion rate was 8.3% (95% CI, 0.067–0.102), whereas the
recurrence rate after 12 months was 2.1%. High-volume
centers had significantly higher en bloc, R0, curative resec-
tion rates, and recurrence rates and lower complication rates
than middle- or low-volume centers. The lesion size, hybrid
ESD, age, stage T1b carcinoma, and treatment outside high-
volume centers were identified as risk factors for non-
curative ESD. CONCLUSION: In Germany, ESD achieves
excellent en bloc resection rates but only modest curative
resection rates. ESD requires a high level of expertise, and
results vary significantly depending on the center’s yearly
case volume.
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
A multicenter registry was established to determine the
overall quality of endoscopic submucosal dissection
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ver the past few years, endoscopic submucosal(ESD) in Germany.
NEW FINDINGS
ESD outcomes depend on the case volume of procedures
being performed in a center. With a case volume of >20
ESDs/y, acceptable results can be achieved.
LIMITATIONS
Not all follow-up data are available, there was inclusion of
hybrid ESD procedures, and the experience level of
individual endoscopists was not registered.
IMPACT
The data collected reflect the status of ESD in Europe and






ATOdissection (ESD) has become a well-established
treatment option for premalignant lesions and early can-
cer (EC) of the gastrointestinal tract.1,2 Compared with
endoscopic mucosal resection, ESD has higher R0 resection
rates, a more accurate histopathologic assessment, and a
reduced recurrence risk, especially for lesions larger than
20 mm.3 Initially established for the stomach, ESD is now
performed in the entire gastrointestinal tract.4
ESD requires a high level of skill and expertise, training
is time-consuming, and learning curves have been long and
tedious.5 Although ESD has become more common, data
from the West still show lower en bloc, R0, and curative
resection rates, and higher recurrence and complication
rates compared with data from Asian countries.6
In Europe, ESD data are mostly limited to single-center
studies or small case series.7–9 Therefore, the German ESD
registry was set up to evaluate and assess the technical
success, curative resection rates, long-term outcomes, and
economic aspects of ESD procedures performed in Germany.
In this article, we present the first results of the German ESD
registry, including en bloc, R0, curative resection rates, and
complication and recurrence rate in 1000 procedures.Abbreviations used in this paper: ASA, American Society of Anesthesi-
ology; CI, confidence interval; EC, early cancer; ESD, endoscopic sub-
mucosal dissection; HGD, high-grade dysplasia; LGD, low-grade
dysplasia; NET, neuroendocrine tumor; OR, odds ratio; OTSC, over-the-
scope-clip; TTSC, through-the-scope-clip.
Most current article
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The German ESD registry is a prospective uncontrolled
multicenter study. All German centers performing ESD were
invited to participate. Data were collected anonymously via
electronic case report form and managed in a centralized
database at the University Hospital of Augsburg. Ethics
approval was granted by the ethics committee of the Ludwig-
Maximilian-University Munich, Germany (study ID:
DRKS00011781). In addition, all other participating centers
received approval from their local institutional review boards.
Patient inclusion commenced on January 1, 2017. This first
evaluation is based on patients included from January 1, 2017–
November 30, 2019.
Participating centers agreed to report all ESDs performed
during the study period. Patient and lesion characteristics (eg,
date of ESD, age, sex, and location), procedure characteristics
(eg, hybrid ESD, conventional or standard ESD, and piecemeal
resection), complications, histopathologic assessment (eg, in-
vasion depth, curative resection rate, and size of the resected
specimen), and follow-up data, material costs, and costs of
hospital-stay (eg, medication, equipment, personal costs, and
intensive care unit monitoring) were reported. All authors had
access to the study data and reviewed and approved the final
manuscript.
Definitions and Follow-up
ESD was performed as a standard ESD procedure or a
hybrid ESD (snare resection after circumferential incision with
or without partial submucosal dissection). En bloc resection
was classified as a resection of the target lesion in 1 piece.
R0-resection was diagnosed when the histopathologicassessment confirmed the horizontal and the vertical margins
to be free of neoplasia. R0 resection was classified as curative in
all benign lesions (low-grade dysplasia [LGD] and high-grade
dysplasia [HGD]). If histopathologic assessment showed EC
with low-risk criteria (depth of submucosal invasion: esopha-
geal squamous cell carcinoma 200 mm, absence of lymphatic
and vascular invasion, well differentiated; esophageal or gastric
adenocarcinoma 500 mm, colorectal adenocarcinoma 1000
mm; absence of lymphatic and vascular invasion; well or
moderately differentiated), the resection was also judged to be
curative.1 When R0 resection could not be confirmed histo-
pathologically, or ECs did not fulfill low-risk criteria, resections
were classified as noncurative. The definition of R0 resection in
Barrett’s esophagus was considered for the histologic entity in
question. For example, for Barrett’s carcinoma and HGD, R0
was accepted, even if lateral margins showed LGD or nondys-
plastic Barrett’s. For LGD, R0 resection was accepted even if the
lateral margins showed nondysplastic Barrett’s mucosa.
Recurrence was considered when carcinoma or HGD was
detected histopathologically in the resected area after initial
resection of a carcinoma or HGD. The same procedure was
followed for lesions with LGD.
Follow-up endoscopic examinations were performed 3 and
12 months after the ESD procedure. Recurrence was diagnosed
when neoplasia was confirmed histopathologically after an
initial R0-situation. For Barrett’s esophagus, recurrence was
considered when carcinoma was detected within the resected
area after initial resection of a carcinoma; analogous proced-
ures were applied to cases with HGD and LGD.
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ATAdapted from the results of the Nagano ESD study group,
centers were subgrouped into the following10: low-volume
centers: <21 ESDs/y (n ¼ 14); middle-volume centers: 21–50
ESDs/y (n ¼ 5); and high-volume centers: >50 ESDs/y (n ¼ 1).
Complications
Predefined complications included perforation, bleeding,
and stricture formation. Bleeding was defined as a hemoglobin
decrease >2 g/dL or clinical signs of bleeding.11 It was cate-
gorized as intraprocedural when it led to the termination of the
procedure or as delayed when it occurred later. Perforation
was defined as a transmural injury leading to intraprocedural
or delayed endoscopic or surgical treatment. Stricture forma-
tion was considered as a complication if it was clinically
symptomatic. Additionally, all reported complications were
grouped according to the grading system of the American So-
ciety for Gastrointestinal Endoscopy.11
Statistical Analysis
For proportions, exact binomial confidence intervals (CIs)
were calculated. Associations between categorical variables
were analyzed using chi-square tests, except for recurrence,
where Fisher exact test was used. P < .05 was considered to be
statistically significant. All calculations were performed using
the software package R (R Foundation for Statistical Computing
2020). For the multivariate analysis, all dependent variables
were coded to be dichotomous. Due to the low case number of
American Society of Anesthesiology (ASA) grade 4 (n ¼ 8), the
ASA grade 3 and 4 categories were grouped together. The
multivariate analysis was performed using binomial logistic
regression. The importance of influencing variables was
assessed via Wald-type test statistics, the odds ratio, and its
95% CI.
Results
Patient and Lesion Characteristics
During a 35-month period (January 2017–November
2019), 1170 patients from 20 participating centers were
included. Only neoplastic lesions (n ¼ 1000) were included
for further evaluation. Figure 1 gives an overview of the
number of patients included by each center.
The number of patients included per center ranged be-
tween 5 and 397 cases. ESD was performed in the esoph-
agus, stomach, duodenum, colon, and rectum. Due to the low
number of duodenal ESDs (17 procedures in 6 centers),
these cases are reported separately. All groups were com-
parable concerning median patient age, sex, and ASA status.
Also, 92.9% of lesions were treatment-naïve. The average
lesion size was 42 x 32mm. Table 1 shows an overview of
patient and lesion characteristics.
Procedure Characteristics
Table 2 summarizes all procedure characteristics.
All lesions. Standard ESD was performed in 885/1000
cases (88.5%), and a hybrid ESD in 115/1000 cases
(11.5%). The overall en bloc resection rate was 924/1000
cases (92.4%); 76 procedures were completed with endo-
scopic mucosal resection (7.6%). R0-resection was achievedin 788/1000 cases (78.8%); curative resection was per-
formed in 723/1000 cases (72.3%). Resection was non-
curative in 277/1000 lesions (27.7%), of which 74 cases
were benign lesions, and 203 cases were carcinomas (R1
n ¼ 126; high-risk situation n ¼ 77).
The median procedure time was defined as the time
from insertion of the endoscope to completion of the ex-
amination (removal of the endoscope). The overall median
procedure time was 85 minutes (range, 15–540 minutes);
the median procedure time in the esophagus was 90 mi-
nutes (range, 15–335 minutes), in the stomach, 90 minutes
(range, 15–540 minutes), in the colon 85 minutes (range,
20–310 minutes), and in the rectum, 85 minutes (range, 15–
480 minutes).
All patients were routinely admitted after ESD for
observation. The median hospital stay was 4 days (range,
1–29). If no complications occurred, the median hospital
stay was 4 days (range, 1–24). In the subgroup with 83
complications, the median hospital stay was 4 days (range,
1–29).
Duodenum. A total of 17 duodenal ESDs were per-
formed in 6 centers, including 6 cases in high-volume, 1 case
in middle-volume, and 10 cases in low-volume centers.
None of the lesions were pretreated. Eleven cases were
neoplastic (6 adenomas with HGD, 3 adenomas with LGD,
and 2 were neuroendocrine tumors [NET]). The en bloc
resection rate of duodenal neoplastic lesions was 81.8%
(n ¼ 8/11), whereas the R0 resection rate was 54.5% (n ¼
6/11). Curative resection was achieved in 5 cases (45.4%).
Bleeding occurred in 18.1% of cases (n ¼ 2/11), including
intraprocedural bleeding (n ¼ 1) and 1 case of delayed
bleeding on the first postinterventional day.
Esophagus. Three hundred six esophageal lesions
were included.
Regarding Barrett’s-related neoplasia, a total of 252/306
esophageal lesions (82.4%) were related to Barrett’s
dysplasia, of which 232 lesions were treatment-naïve
(94.0%). Two lesions were located in the upper, 11 in the
middle, and 239 in the distal esophagus. The 252 lesions are
subgrouped into 234 adenocarcinomas (G1 n ¼ 132; G2 n ¼
78; G3 n ¼ 23; G4 n ¼ 1), 10 lesions with HGD, and 8 lesions
with LGD. En bloc rate was 243/252 cases (96.4%), R0- rate
was 193/252 cases (76.6%), and curative resection rate was
182/252 cases (71.2%).
Regarding squamous cell neoplasia, a total of 54 squa-
mous cell neoplasias were resected in the esophagus, and
their distribution is as follows: 20 lesions in the upper, 27
lesions in the middle, and 7 lesions in the distal esophagus.
Forty-nine lesions were treatment-naive (90.7%). The his-
topathologic assessment showed 51 squamous cell carci-
nomas (G1 n ¼ 12; G2 n ¼ 28; G3 n ¼ 11), 2 lesions with
HGD, and 1 lesion with LGD. En bloc rate was 98.1% (53/
54), R0 rate was 81.5% (44/54), and curative resection rate
was 46.2% (25/54).
Stomach. Two hundred thirty-six gastric lesions were
treated using ESD: 48 in the proximal, 61 in the middle, and
127 in the distal stomach. Also, 218/236 lesions were
resected en bloc (92.4%) with an R0-rate of 190/236
(80.5%). In 170/236 cases, resection was curative (72.0%).
397
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Figure 1. ESDs from 20 participating centers.





ATHistopathologic findings showed 167 adenocarcinomas (G1
n ¼ 84; G2 n ¼ 61; G3 n ¼ 22), 12 cases of HGD, 43 cases of
LGD, and 14 NETs.
Colon. Seventy-eight lesions were located in the co-
lon (cecum n ¼ 12; ascending colon n ¼ 18; transverse
colon n ¼ 8; descending colon n ¼ 7; and sigmoid colon
n ¼ 33). En bloc resection was performed in 66/78
cases (84.6%) with an R0 rate of 56/78 cases (71.8%)
and a curative resection rate of 53/78 cases (67.9%).
The histopathologic assessment showed 10 adenocarci-
nomas (G1 n ¼ 4; G2 n ¼ 6), 24 cases of HGD, and 44
cases of LGD.
Rectum. A total of 380 lesions were resected in
the rectum. En bloc resection was achieved in 344/380
cases (90.5%), R0-resection in 305/380 cases (80.3%),
and curative resection in 293/380 cases (77.1%).
Histopathology showed 57 adenocarcinomas (G1 n ¼ 15; G2
n ¼ 41; G3 n ¼ 1), 194 cases of HGD, 121cases of LGD, and 8




Age, median (range), y 69 (29–94) 69 (29–
Sex, n (%)
Male 703 (70.3) 246 (80
Female 297 (29.7) 60 (19
ASA grade 1/2/3/4 340/493/159/8 79/167/5
Specimen size, median (mm) 42 x 32 40 x 2
Treatment-naive lesion (%) 930 (93.0) 281 (91Complications
Complications occurred in 83/1000 ESD procedures
(8.3%; Table 2). The delayed bleeding rate was 2.6% (8/
306) after esophageal, 5.9% after gastric (14/236), and
1.0% after rectal ESD (4/380). No delayed bleeding
occurred after colonic ESD. Eight patients required blood
transfusion after delayed bleeding (3 after esophageal and 5
after gastric ESD). Bleeding was successfully treated by
clipping, coagulation, or combination of both. All bleedings
were moderate adverse events.
Perforation was reported in 42 cases (4.2%); perforation
rate was 2.6% in the esophagus (8/306), 4.2% in the
stomach (10/236), 14.1% after colonic ESD (11/78), and
3.4% after rectal ESD (13/380). None of the esophageal
perforations needed surgical treatment; 6 perforations were
treated with through-the-scope-clips (TTSC), 1 perforation
was treated with an over-the-scope clip (OTSC, OVESCO,
Tübingen, Germany), and 1 perforation was managed with
antibiotic treatment and a nil-per-os diet. Nine of 10gus Stomach Colon Rectum
236 78 380
90) 69 (34–89) 68 (35–88) 69 (30–94)
.4) 154 (65.3) 53 (77.9) 250 (65.8)
.6) 82 (34.7) 25 (32.1) 130 (34.2)
7/3 57/121/57/1 30/40/8/0 174/165/37/4
9 38 x 29 35 x 28 47 x 37
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ATstomach perforations were managed endoscopically, 2x via
OTSC, 7x via TTSC, and 1 patient underwent surgery. The
highest perforation rate was documented in the colon, in
11/78 cases (14.1%). Six perforations were treated with
standard TTSC and 3 with an OTSC. Two patients with
perforation who could not be managed endoscopically un-
derwent surgery (1x partial colectomy, 1x right-sided
hemicolectomy). Two of 13 rectal perforations underwent
surgery; 1 patient needed partial colectomy, and another
developed fever and abdominal pain on the sixth post-
procedural day. This was caused by a retroperitoneal ab-
scess that was treated using trans-anal surgery and
drainage of the abscess. The remaining 11 rectal perfora-
tions were managed endoscopically, 8x with conventional
TTSC, in 1 case via endoscopic vacuum sponge therapy and
2x via OTSC. Perforations were graded as mild (n ¼ 36),
severe (n ¼ 5), and moderate (n ¼ 1).
Fifteen cases of esophageal stricture formation were
reported. In 1 case, stricture formation occurred, although
less than one third of the circumference was resected. Nine
cases of esophageal stricture formation were reported after
ESD of at least two thirds of the circumference. Esophageal
stricture occurred in 5 of 15 cases after circumferential ESD.
All esophageal stricture formations were moderate
complications.Recurrence Rate
Endoscopic follow-up was recommended for 857 pa-
tients, in 692 cases after curative resection and in 165 cases
after noncurative resection.
Follow-up after 3 months. Follow-up endoscopy af-
ter 3 months was documented in 682/857 cases (79.6%).
Local recurrence was diagnosed in 16/682 cases (2.3%).
Seven local recurrences occurred in the esophagus (2.8%),
4 in the stomach (2.3%), 1 in the colon (3.0%), and 4 cases
in the rectum (1.8%). In 4 cases, recurrence occurred
after curative resection, once after resection of an HGD,
whereas 3 lesions were carcinomas. In 12 cases, a recur-
rence after noncurative resection was documented; of these,
4 lesions were benign, but there was an R1 situation,
whereas 8 lesions were carcinomas. These had undergone
R1 resection in 3 cases, whereas 5 were with high-risk
histologic criteria.
Follow-up after 12 months. Follow-up endoscopy at
12 months was documented in 660/857 cases (77.0%).
Local recurrence was diagnosed in 14/660 cases (2.1%).
Seven local recurrences occurred in the esophagus (2.8%), 5
in the stomach (3.2%), 1 in the colon (2.4%), and 1 case was
reported in the rectum (0.5%). In 5 cases, a recurrence
occurred after curative resection, once after resection of an
LGD, and once after resection of an HGD, whereas 3 lesions
were carcinomas. In 9 cases, a recurrence after noncurative
resection was documented; of these, 3 lesions were benign,
but there was an R1 situation, whereas 6 lesions were
carcinomas. These had undergone R1 resection in 5 cases,
whereas 1 case was with high-risk histologic criteria.
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Figure 2. Endoscopic follow-up and recurrence; oncologic therapy included radiation, chemotherapy, or combination of both.





ATOutcome According to ESD Caseload per Year
Figure 3 shows the case volume per year of participating
centers.Procedure Characteristics
Procedure time varied from 80 minutes (median, range
15–480) in the high-volume center to 85 minutes (median,
140
31 29 24 23 22 20 20
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Figure 3. Centers and numbers of ESD/y.
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ATrange 25–540) in middle-volume and 87.5 minutes (median,
range 20–355) in low-volume centers. Concerning en bloc
resection, the high-volume center achieved the highest rate
with 96.0%, followed by middle-volume (93.9%) and low-
volume centers (86.3%). The high-volume center achieved
the highest R0-resection rate with 87.9%. The R0-resection
rate decreased from 77.3%, in middle-volume centers, to
68.5% in low-volume centers. The curative resection rate
was 82.9% in the high-volume center, followed by 69.8% in
middle-volume centers and 61.0% in low-volume centers
(Table 3).
Regarding standard ESD versus hybrid ESD according to
case volume, the highest number of standard ESDs wasTable 3.Comparison Caseloads per Year
ESD volume/y n  20/y
Centers (n) 14
Number of ESDs/y 115
Number of ESDs (total) 308
Specimen size, median (mm) 39 x 31
Location (esophagus/stomach/colon/rectum) 74/91/23/120
En bloc rate (%) 266 (86.3)
R0 (%) 211 (68.5)
Curative resection rate (n%) 188 (61.0)




Follow-up 3 mo documented (n%) 198 (76.1)
Recurrence after 3 mo (n%) 4 (2.0)
Follow-up 12 mo documented (n%) 169 (65.0)
Recurrence after 12 mo (n%) 11 (6.5)performed in the high-volume center with 371/397 cases
(93.5%). Here, en bloc resection was achieved in 367/371
cases (98.9%), R0 resection in 337/371 cases (90.8%), and
curative resection in 317/371 cases (85.4%). A total of 26/
397 ESDs in the high-volume center was performed as
hybrid procedures (6.5%) with an en bloc rate of 14/26
cases (53.8%), R0 rate of 12/26 cases (46.1%), and curative
resection rate of 12/26 cases (46.1%).
Middle-volume centers performed standard ESD in 272/
295 cases (92.2%); for standard ESDs, an en bloc rate of
97.7% was achieved (266/272 cases), an R0 rate of 80.8%
(220/272 cases), and a curative resection rate of 72.3%




40 x 30 45 x 35
102/69/26/98 130/76/29/162 .0071
277 (93.9) 381 (96.0) <.00001
228 (77.3) 349 (87.9) <.00001
206 (69.8) 329 (82.9) <.00001
38 (12.9) 12 (3.0) <.00001
238 (80.6) 359 (90.4) .0010
144 (60.5) 340 (94.7) <.00001
6 (4.1) 6 (1.7) .81
211 (88.6) 280 (78.0) <.00001
3 (1.4) 0 (0) <.00001





ATcases (7.8%), with an en bloc rate of 47.8% (11/23 cases)
and R0 and curative resection rate of 34.7% (8/23 cases),
respectively.
In low-volume centers, the proportion of standard ESDs
was 242/308 cases (78.6%). En bloc rate was 236/242
cases (97.5%), R0 rate was 184/242 cases (76.0%), and
curative resection rate was 161/242 cases (66.5%). Thus,
the highest amount hybrid ESDs with 66/308 ESDs (21.4%)
was performed in low-volume centers, with an en bloc
resection rate of 45.4% (30/66 cases), an R0 resection rate
of 40.9% (27/66 cases), and a curative resection rate of
40.9% (27/66 cases).
Complications according to case volume. The
highest complication rate was reported in middle-volume
centers with 38 documented complications (12.9%): 13
episodes of delayed bleeding, 18 perforations (all managed
endoscopically), and 7 strictures. In low-volume centers, 33
complications (10.7%) were documented: 5 cases of
delayed bleeding, 20 perforations with 2 subsequent sur-
geries, as well as 8 documented strictures. In the high-
volume center, 12 complications were documented
(3.0%): 8 cases of delayed bleeding and 4 perforations, 3 of
which needed further surgical treatment. No stricture was
documented (Table 3).
Recurrence. Regarding follow-up after 3 months, in
low-volume centers, follow-up data were available for 198/
260 patients (76.1%). Four of 198 cases developed local
recurrence after 3 months (2.9%). Middle-volume centers
reported 6 local recurrent lesions in 144 follow-up endo-
scopic examinations (4.1%). In the high-volume centers, 6/
340 recurrent lesions were documented (1.7%; Table 3).
Regarding follow-up after 12 months, in low-volume
centers, follow-up data were available for 169/260 pa-
tients (65.0%). Eleven of 169 cases developed local recur-
rence after 3 months (6.5%). Middle-volume centers
reported 3/211 recurrent lesions (1.4%). In the high-
volume study cohort, no recurrent lesion was documented
(Table 3).Variables Influencing Favorable Outcome: A
Multivariate Analysis
In this section, possible variables influencing the
achievement of en bloc, R0, and curative resection were
investigated. It was also investigated which variables in-
crease the risk of complications as well as recurrences.
Analyzed parameters included: age, sex, ASA status, lesion
size, standard vs hybrid ESD, location, histopathologic
findings (LGD, HDG, and carcinoma T1 vs carcinoma T1b),
and caseload. All figures of the multivariate analysis can be
found in the supplementary file.
The en bloc resection rate was significantly influenced
by lesion size (P ¼ .008; odds ratio [OR], 0.97; 95% CI, 0.94–
0.99) as well as by performing a standard ESD (P < .01; OR,
58.73; 95% CI, 28.32–121.81; Supplementary Figure 1).
Patient age (P ¼ .041; OR, 0.98; 95% CI, 0.06–0.99) and
lesion size (P ¼ .001; OR, 0.97; 95% CI, 0.96–0.99) signifi-
cantly influenced R0 resection rates positively. In addition,
an R0 situation was significantly more frequently achievedafter performing standard ESD (P < .01; OR, 8.70; 95% CI,
5.38–14.08). Resection of a LGD (P < .01; OR, 3.02; 95% CI,
1.69–5.38), HGD (P < .01; OR, 4.88; 95% CI, 2.63–9.05) and
a T1a carcinoma (P ¼ .001; OR, 2.34; 95% CI, 1.40–3.92) is
associated with a higher likelihood of an R0 situation
compared with T1b carcinomas. Also, performing ESD at
high-volume centers makes R0 resection statistically more
likely (P < .01; OR, 2.63; 95% CI, 1.68–4.14; Supplementary
Figure 2).
Influential variables making achievement of curative
resection more likely were lesion size (P ¼ .013; OR, 0.98;
95% CI, 0.97–0.99) and performance of standard ESD (P <
.01; OR, 5.0; 95% CI, 3.07–8.14). Resection of an LGD (P <
.01; OR, 17.29; 95% CI, 9.50–31.41), HGD (P < .01; OR,
24.87; 95% CI, 13.27–46.16) and T1a carcinoma (P < .01;
OR, 8.55; 95% CI, 5.17–14.14) is significantly more often
associated with R0 resection compared with T1b carci-
nomas. Treatment at a high-volume center also makes R0
resection statistically more likely (P < .01; OR, 2.19; 95% CI,
1.43–3.35; Supplementary Figure 3).
Compared with complications after rectal ESD, compli-
cations of squamous cell neoplasia (P ¼ .019; OR, 5.69; 95%
CI, 2.14–15.15), gastric lesions (P ¼ .018; OR, 2.63; 95% CI,
1.17–5.91), and lesions in the colon (P < .01; OR, 2.95; 95%
CI, 1.19–7.33) occurred significantly more frequently. Per-
forming a standard ESD (P < .029; OR, 0.48; 95% CI, 0.25–
0.93) as well as treatment at a high-volume center (P <
0.01; OR, 1.21; 95% CI, 0.711–2.06) reduced the risk of
complications (Supplementary Figure 4).
Squamous cell neoplasia (P < .004; OR, 28.62; 95% CI,
2.97–275.43) resulted in a statistically higher recurrence
rate at 3 months compared with rectal lesions. All other
variables studied showed no statistical significance con-
cerning recurrence rate at 3 months (Supplementary
Figure 5).
The risk of recurrence at 12 months was increased for
squamous cell neoplasia (P ¼ .025; OR, 24.69; 95% CI, 1.48–
109.65). Treatment in high-volume (P¼ .047; OR, 0.15; 95%
CI, 0.07–0.65) and middle-volume centers (P ¼ .025; OR,
0.20; 95% CI, 0.05–0.81) is associated with a lower risk of
recurrence compared with low-volume centers
(Supplementary Figure 6).Discussion
ESD is a technically demanding resection technique.
Although comprehensive data exist from Asian countries,
ESD data from the Western world are primarily from
retrospective, single-center studies.8,9,12 Current ESD qual-
ity standards in the West are based mainly on prospective
studies from Asian countries with high case numbers and
excellent study outcomes.13 Therefore, the German ESD
registry was established to evaluate the use and the quality
of ESD in Germany and to create a broader scientific data-
base for Western settings.
In this study, we present the first results of the German
ESD registry, including en bloc, R0, curative resection rates,
complication, and recurrence rates. A satisfactory overall en
bloc resection rate of 92.4% (95% CI, 0.90–0.94) was
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ATachieved; however, when compared with Asian data, the R0
and curative resection rates were considerably lower with
78.8% (95% CI, 0.76–0.81) and 72.3% (95% CI, 0.69–0.75),
respectively. Only 70 (7.0%) of the lesions were pretreated.
A possible explanation may be that ESD has gained impor-
tance as a treatment modality and a primary intervention
option in Europe over the last years.
In a prospective national survey from France, results
from 16 centers with 288 ESDs were evaluated. The en bloc
rate was 91.7%, the R0 rate was 72.9%, and the complica-
tion rate was 14.1%.14 The results were compared with a
2011 study of the same study group. A significant increase
in the en bloc rate from 77.1% to 91.7% and a decrease in
the complication rate from 29.2% to 14.1% were shown; the
R0 rate did not change significantly.15 Although the German
ESD registry results are better than the results from the
French survey, they still fall short of the outcomes from
Asian studies where en bloc, R0, and curative resection rates
of above 97%, 91%, and 89%, respectively, have been
reported.13,16,17Effect of Lesion Location
Unlike in most published studies, the results presented
here refer to ESDs performed in different organs, which may
have had a considerable effect on study outcomes. The
highest en bloc rate of 96.7% in the esophagus (95% CI,
0.94–0.98) contrasts with an en bloc rate of 84.6% (95% CI,
0.75–0.92) in the colon. The highest R0 rate of 80.5% (95%
CI, 0.75–0.85) was in the stomach, and the lowest rate with
71.7% (95% CI, 0.60–0.81) was in the colon. The highest
curative resection rate of 77.1% (95% CI, 0.73–0.81) was in
the rectum, whereas the lowest was in the esophagus with
67.6% (95% CI, 0.62–0.73). A retrospective Italian self-
report survey yielded similar results.18
Comparing ESD in the esophagus with published data
from other European centers, no differences in en bloc
resection, R0 resection, and curative resection rate were
found.19,20 For gastric lesions, European single-center
studies reported en bloc resection rates ranging from
90%–100% and R0 resection rates of 64.3%–92.8%.9,21,22
The present study results with an en bloc rate of 92.3%
(95% CI, .88–0.95) and an R0 resection rate of 80.5% (95%
CI, 0.75–0.85) are similar to these data.
In 2016, Sauer et al published a case series of 182
colorectal ESDs >20 mm. Most of the lesions were locatedTable 4.Hospital Volume and ESD Complications
Reference Patients (n) Study design Localizatio
Odagiri et al26 12,899 Retrospective cohort study Esophagea
Murata et al27 27,385 Retrospective cohort study Gastric
Odagiri et al28 7567 Retrospective cohort study Colorectal
HVHs, high-volume hospitals; LVHs, low-volume hospitals; MV
tals; VLVHs, very low-volume hospitals.proximal to the rectum. A high en bloc rate of 88.4% was
achieved, the R0 resection rate was 62.6%, and the perfo-
ration rate was 9.3%.12 In our study, comparable en bloc, R0
resection, and perforation rates are demonstrated for
colonic lesions. Nevertheless, there is still a lack of
comprehensive and broad-based data for colonic ESD in
Europe.
For rectal ESD, numerous European publications have
shown en bloc and R0 resection rates between 72.7%–96%
and 67.2%–84.8%, respectively.7,8,23,24 In the German ESD
registry, rectal ESD data showed a high en bloc resection
rate of 90.5% (95% CI, 0.87–0.93) and R0 resection rate of
80.2% (95% CI, 0.76–0.84).
In a cohort of patients who underwent follow-up after 3
months, a total of 16 recurrences (2.3%) was documented.
In the second follow-up documented after 12 months, 14
recurrences were registered (2.1%). This is within the range
of the data published from Japan.25 It is worth mentioning
that only 4 of the 16 recurrences after 3 months and 5 of the
14 recurrences after 12 months occurred after curative
resection. However, it could be possible that the 12 re-
currences after 3 months and the 9 recurrences after 12
months, and after initial noncurative resection, were meta-
chronous lesions and not true recurrences.Effect of Case Volume
The Nagano ESD study group published a retrospective
multicenter study in which they investigated the outcome
after ESD for gastric neoplasia. The authors divided the
participating centers into high-volume (>30 ESDs/y) and
low-volume centers (<30 ESDs/y). A significant difference
in outcome between high-volume and low-volume centers
could not be demonstrated.10
Based on our data, the ESD landscape in Germany
proved to be more heterogeneous, with a predominant
number of centers performing <20 ESDs/y. In contrast to
the Nagano ESD study group, which included only gastric
ESDs, our analysis of all lesions showed significant differ-
ences in the en bloc resection rate (P < .00001), the R0
resection rate (P < .00001), and the curative resection rate
(P < .00001). Also, complications occurred significantly less
frequently in the high-volume centers than in the other 2
groups (P < .00001).
To date, there are no studies from the western world
that report on the influence of the ESD caseload per year onn Center definitions ESDs/y
Complication
rate (%)
l VLVHs 8 LVHs 9–17 HVHs 18–38 VHVHs 39 3.3
LVHs <50 MVHs 50–100 HVHs >100 3.5
VLVHs 18 LVHs 19–35 HVHs 36–58 VHVs 59 4.6
Hs, middle-volume hospitals; VHVs, very high-volume hospi-





ATpatients’ outcomes. Retrospective Japanese studies with a
high number of patients assessed the impact of hospital
volume per year on complications after ESD in the esoph-
agus, stomach, and colorectum (Table 4). It was shown that
low-volume hospitals had significantly more complications
after esophageal ESD.26 Murata et al27 showed that ESDs in
the upper gastric body had significantly fewer complications
than low-volume and middle-volume hospitals. In a further
retrospective study, the lower occurrence of complications
in colorectal ESD and its significant association with higher
hospital volume was reported.28
Concerning the recurrence rate after 3 months, no sig-
nificant difference was shown in our data among the 3
groups (P ¼ 0.81) except for the recurrence rate after 12
months (P < .00001).Risk Factors for Failed Curative ESD
Prediction models and risk analyses for noncurative
ESD exist predominantly for gastric ESDs. Risk factors for
noncurative ESD have been postulated to be, for example,
age, gender, lesion size, advanced histology, and location in
the upper gastric body.29,30 We identified lesion size and
hybrid ESD as risk factors for failed en bloc resection.
Lesion size, age, and hybrid ESD were shown to be risk
factors for R1 resection, in addition to the presence of a
T1b stage and treatment outside of high-volume centers.
Risk factors for noncurative resection were hybrid ESD and
T1b stage and treatment outside high-volume centers. The
complication risk is higher for squamous neoplasms,
gastric lesions, and colonic lesions than for rectal lesions.
Within the parameters studied, only squamous cell
neoplasia could be identified as a predictor of increased
risk of recurrence. After 12 months, an increased risk of
recurrence is present for treatment in low-volume centers
in addition to squamous neoplasia. For this reason, treat-
ment by hybrid ESD should be avoided, lesion selection
should be made carefully, and patients should be treated in
high-volume centers.
Limitations of this study include the fact that, although a
total of 20 centers have included patients to the ESD reg-
istry, it remains questionable whether this represents the
entire ESD landscape in Germany. Also, not all follow-up
examinations were recommended or performed, which
may have influenced the reported recurrence rate. In addi-
tion, the results may have been inferior in terms of en bloc
and R0 resection due to the evaluation of hybrid ESDs.
Finally, individual endoscopist experience was not analyzed,
and it is unclear how many endoscopists at what level of
expertise were involved in the ESD procedures.
In summary, this study provides current data on ESD in
Germany. Satisfactory en bloc and R0 resection rates
contrast to a curative resection rate that needs to be
improved. Acceptable en bloc and R0 values can be achieved
with a case volume of >20 ESDs/y. However, R0 and
curative resection rates >80% were only achieved in the
high-volume center. The data presented here suggest that
ESD is an efficient treatment method that experts should
perform with an appropriate yearly caseload. Furtherprospective multicenter studies should follow to optimize
and establish ESD in the West.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://doi.org/10.1053/
j.gastro.2021.06.049.References
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